Top

PharmacoEconomics

Published in:

01-06-2014 | Original Research Article

Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?

Authors: Klazien Matter-Walstra, Dirk Klingbiel, Thomas Szucs, Bernhard C. Pestalozzi, Matthias Schwenkglenks

Published in: PharmacoEconomics | Issue 6/2014

Abstract

Background

The European Quality of Life–5 Dimensions (EQ-5D) instrument combines questionnaire responses into a single utility estimate using country-specific value sets. Countries without a national value set are advised to select one based on geographic proximity. In the absence of a Swiss value set, we used foreign value sets to gain insights into their appropriateness for use with Swiss cancer patients.

Methods

EQ-5D health states and visual analogue scale (VAS) ratings were collected in one German and three Swiss oncology trials. Utilities were calculated based on the United Kingdom (UK), German (GE), French (FR) and European Union (EU) value sets. Resulting differences and Pearson partial correlation coefficients with corresponding VAS ratings were assessed.

Results

In total, 202 Swiss and 154 German patients undergoing cancer treatment completed at least two EQ-5D forms. The mean difference between GE-based and FR-, UK- or EU-based utilities was significantly larger than the differences between the latter. The absolute mean difference between utilities and VAS ratings was highest for GE-based utilities, for Swiss (0.170, 95 % confidence interval [CI] 0.146–0.194) and German patients (0.174, 95 % CI 0.145–0.202). The correlation between GE-based utilities and VAS ratings was the lowest (r = 0.36, 95 % CI 0.33–0.40); the highest was between FR-based utilities and VAS ratings (r = 0.43, 95 % CI 0.39–0.46).

Conclusion

For Switzerland, utility calculations based on the German or French value set would be an obvious choice. Our results suggest that the German value set may not be the most appropriate for use with Swiss cancer patients. The French and EU value sets may be relevant alternatives and improve international comparability.

Available only for authorised users

Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–43.PubMedCrossRef

Bailey H, Kind P. Preliminary findings of an investigation into the relationship between national culture and EQ-5D value sets. Qual Life Res. 2010;19(8):1145–54.PubMedCrossRef

Norman R, Cronin P, Viney R, King M, Street D, Ratcliffe J. International comparisons in valuing EQ-5D health states: a review and analysis. Value Health. 2009;12(8):1194–200.PubMedCrossRef

Bernert S, Fernandez A, Haro JM, Konig HH, Alonso J, Vilagut G, et al. Comparison of different valuation methods for population health status measured by the EQ-5D in three European countries. Value Health. 2009;12(5):750–8.PubMedCrossRef

Heijink R, van Baal P, Oppe M, Koolman X, Westert G. Decomposing cross-country differences in quality adjusted life expectancy: the impact of value sets. Popul Health Metrics. 2011;9(1):17.CrossRef

Kharroubi SA, O’Hagan A, Brazier JE. A comparison of United States and United Kingdom EQ-5D health states valuations using a nonparametric Bayesian method. Stat Med. 2010;29(15):1622–34.PubMed

Knies S, Evers SM, Candel MJ, Severens JL, Ament AJ. Utilities of the EQ-5D: transferable or not? Pharmacoeconomics. 2009;27(9):767–79.PubMedCrossRef

Nan L, Johnson JA, Shaw JW, Coons SJ. A comparison of EQ-5D index scores derived from the US and UK population-based scoring functions. Med Decis Making. 2007;27(3):321–6.CrossRef

Oppong R, Kaambwa B, Nuttall J, Hood K, Smith RD, Coast J. The impact of using different tariffs to value EQ-5D health state descriptions: an example from a study of acute cough/lower respiratory tract infections in seven countries. Eur J Health Econ. 2013;14:197–209.PubMedCrossRef

10.

Szende A, Oppe M, Devlin N. EQ-5D value sets, inventory, comparative review and user guide. The Netherlands: Springer; 2007.CrossRef

11.

Greiner W, Claes C, Busschbach JJ, von der Schulenburg JM. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ. 2005;6(2):124–30.PubMedCrossRef

12.

Chevalier J, de Pouvourville G. Valuing EQ-5D using Time Trade-Off in France. Eur J Health Econ. 2013;14(1):57–66.PubMedCrossRef

13.

Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, et al. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ. 2003;4(3):222–31.PubMedCrossRef

14.

Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL, editors. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005. p. 143–7.

15.

Whynes DK. Correspondence between EQ-5D health state classifications and EQ VAS scores. Health Qual Life Outcomes. 2008;6:94.PubMedCentralPubMedCrossRef

16.

Gunther OH, Roick C, Angermeyer MC, Konig HH. The responsiveness of EQ-5D utility scores in patients with depression: a comparison with instruments measuring quality of life, psychopathology and social functioning. J Affect Disord. 2008;105(1–3):81–91.PubMedCrossRef

17.

Stark RG, Reitmeir P, Leidl R, Konig HH. Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany. Inflamm Bowel Dis. 2010;16(1):42–51.PubMedCrossRef

18.

Badia X, Herdman M, Roset Dipstat M, Ohinmaa A. Feasibility and validity of the VAS and TTO for eliciting general population values for temporary health states: a comparative study. Health Serv Outcomes Res Methodol. 2001;2:51–65.

19.

Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.

20.

Rutten-van Molken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest. 2006;130(4):1117–28.PubMedCrossRef

21.

Whynes DK. Does the correspondence between EQ-5D health state description and VAS score vary by medical condition? Health Qual Life Outcomes. 2013;11(1):155.PubMedCentralPubMedCrossRef

22.

Perneger TV, Combescure C, Courvoisier DS. General population reference values for the French version of the EuroQol EQ-5D health utility instrument. Value Health. 2010;13(5):631–5.PubMedCrossRef

Title: Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?
Authors: Klazien Matter-Walstra
Dirk Klingbiel
Thomas Szucs
Bernhard C. Pestalozzi
Matthias Schwenkglenks
Publication date: 01-06-2014
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 6/2014
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.1007/s40273-014-0151-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Using the EuroQol EQ-5D in Swiss Cancer Patients, Which Value Set Should be Applied?

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2014

Cost Effectiveness of a Pharmacist-Led Information Technology Intervention for Reducing Rates of Clinically Important Errors in Medicines Management in General Practices (PINCER)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation

Modelling Technique, Structural Assumptions, Input Parameter Values: Which Has the Most Impact on the Results of a Cost-Effectiveness Analysis?

Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches

Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines

When to Use Discrete Event Simulation (DES) for the Economic Evaluation of Health Technologies? A Review and Critique of the Costs and Benefits of DES